Indian Journal of Biochemistry & Biophysics Vol. 50, October 2013, pp. 357-362

Review

Molecular Diagnosis of Disorders: Current Global Scenario

K Vaidyanathan Dept of Biochemistry, Pushpagiri Institute of Medical Science & Research Center, Tiruvalla 689 101, Kerala, India

Received 07 July 2013; revised 29 August 2013

Urea cycle disorders are a group of inborn error of metabolism, characterized by , metabolic alkalosis and clinical features of encephalopathy. These are among the commonest types of inborn errors of metabolism with a frequency of 1 in 8,000 to 1 in 30,000 in different population. This encompasses 5 major disorders, corresponding with deficiency of each step in the urea cycle, namely ornithine transcarbamoylase (OTC) deficiency, argininosuccinate lyase (ASL) deficiency, carbamoyl phosphate synthetase (CPS) deficiency, and . The most important clinical presentation is neurological abnormalities. The severity of UCD is correlated to extent of hyperammonemia. Early diagnosis and treatment are essential for successful patient outcome. Various modalities of treatment have been recommended; namely, treatment aimed at reducing level, including drugs like and sodium phenyl butyrate, neuroprotective strategies, low diet, transplantation and hepatocyte transplantation. Molecular diagnosis is important to identify the pathogenesis of these disorders as well as it helps in prognosis. This review intends to summarize the important aspects of molecular diagnostic studies on urea cycle disorders.

Keywords: Arginase deficiency, Citrullinemia, Carbamoyl phosphate synthetase I deficiency, Hyperammonemia, Molecular diagnosis, Ornithine trans carbamoylase deficiency, Urea cycle disorders

Introduction Deficiency of any of the urea cycle may Urea cycle disorders (UCD) are a group of inborn result in hyperammonemia. When the block is in one errors of metabolism characterized by increase of the earlier steps, the condition is more severe, since in plasma ammonia concentration above 150 µmol/L, ammonia itself accumulates (“proximal UCD”). normal anion gap and blood glucose and in most Deficiencies of later enzymes (argininosuccinate cases, metabolic alkalosis1. They are among the most syntehtase, argininosuccinate lyase and arginase) common types of inborn errors of metabolism2,3. results in the accumulation of other intermediates There are five main disorders, namely ornithine which are less toxic and hence symptoms are less transcarbamoylase (OTC) deficiency, argininosuccinate (“distal UCD”). Clinical symptoms include , lyase (ASL) deficiency, carbamoyl phosphate synthetase irritability, lethargy and severe mental retardation. (CPS) deficiency, citrullinemia and argininemia. Infants appear normal at birth, but within days The over-all incidence of UCD is reported as 1 progressive lethargy sets in5. in 8,000 to 1 in 30,000 in different populations4,5. Important characteristics of UCD are summarized in Table 1. ——————

*Corresponding author: Clinical features E-mail: [email protected] Tel.: +91 469 2700 755/Ext 526; Fax: +91 469 2600020 Children are usually born full-term with no Abbreviations: ALD, argininosuccinate lyase deficiency; ARG1, obstetric risk factors and then exhibit progressive arginase; ARGD, arginase deficiency; ASD, argininosuccinate lethargy, hypothermia and apnea related to high synthetase deficiency; ASL, arginino succinate lyase; ASS, ammonium levels. Encephalopathy is seen and is argininosuccinate synthetase; BCAA, branched chain amino acid(s); cGMP, cyclic guanosine mono phosphate; CNTF, ciliary characterized by brain edema and swollen astrocytes neurotrophic factor; CPS, carbamoyl phosphate synthetase; due to accumulation of , resulting in CPSD, carbamoyl phosphate synthetase deficiency; CSF, cerbro osmotic shifts of water into the cells. They may spinal fluid; HDACI, histone deacetylase inhibitor; MAPK, also present in later infancy, childhood or adulthood mitogen activated protein kinase; MLPA, multiplex ligation- with episodic mental changes including lethargy dependant probe amplification, NMDA, N-methyl D-aspartate, 5 OTC, ornithine trans carbamoylase, OTCD, ornithine trans and behavioral changes . Neurologic abnormalities carbamoylase deficiency, UCD, urea cycle disorder(s). like , , cognitive impairment, 358 INDIAN J. BIOCHEM. BIOPHYS., VOL. 50, OCTOBER 2013

Table 1—Important characteristics of UCD5 Disease deficit Features Hyperammonemia type I CPS – 1 Very high ammonia levels in blood. Autosomal recessive. Mental (CPSD) retardation. Comparatively rare. Hyperammonemia type II OTC Ammonia level high in blood. Increased glutamine in blood, CSF and (OTCD) urine. Orotic aciduria due to channeling of carbamoyl phosphate into pyrimidine synthesis. X-linked. Commonest type. Citrullinemia ASS Autosomal recessive. High blood levels of ammonia and (ASD) (>1000–5000 µm, normal 10-20 µm). Citrullinuria (1-2 g/day). Argininosuccinic aciduria ASL Argininosuccinate in blood and urine. Friable brittle tufted hair (ALD) (Trichorrhexis nodosa). Hyperargininemia Arginase Mildest variety. Hyperammonemia is less severe. increased in blood and CSF. Instead of arginine, cysteine and are lost in urine.

Fig. 1—The flow chart for diagnosing UCD

psychiatric illness, intellectual and developmental It can lead to changes in neurotransmitter levels. abnormalities are also seen6,7. For example, acute hyperammonemia can lead to activation of NMDA receptors, leading to excitotoxic Laboratory diagnosis cell death, changes in energy metabolism and Amino acid analysis and urine orotate measurement 6 alterations in astrocycte protein expression . Elevation can help to distinguish between the different types of of glutamine and reduction of myoinositol are UCD. Molecular genetic analysis or enzyme assays is 8 also observed . Chronic hyperammonemia produces generally used for confirmatory diagnosis1. Defects in adaptive responses in NMDA receptor and impairment enzymes of urea cycle are detected in neonatal blood 5 of glutamine/nitric oxide/cGMP pathway producing by tandem mass spectrometry . The flow chart for 8 alterations in cognitive functions and learning . Brain diagnosing UCD is given in Fig. 1A and B1. tissue is more susceptible to harmful effects of 9 Hyperammonemia ammonium in childhood than during adulthood . Hyperammonemia in UCDs affects central nervous Neuroprotective strategies like NDMA receptor system, leading to changes in mental status, brain antagonists, nitric oxide inhibitors, , acetyl-L- edema, seizures, coma and potentially death8. carnitine, ciliary neurotrophic factor (CNTF) and VAIDYANATHAN: MOLECULAR DIAGNOSIS OF UREA CYCLE DISORDERS 359

inhibitors of MAPKs and glutamine synthetase have A single study has done multiplex ligation-dependant been used for the treatment of UCD8,9. probe amplification (MLPA) method to detect ; this has been described under the section Treatment concerned. It is recommended that plasma ammonia level 10 should be measured in all patients with encephalopathy . Arginase deficiency (ARGD) Ammonia levels >200 µmol/L increases morbidity pattern in ARG1 in hyperargininemia and mortality significantly in patients with UCD11. in a Brazilian population has identified 8 mutations, Low protein diet is the most important step in the including 5 novel ones in 16 patients. Patients with dietary management of UCD12. Sodium phenyl p.R308Q mutation have shown higher residual ARG1 butyrate and glycerol phenyl butyrate are used in the decreased activity, but no distinguishable phenotype21. treatment of UCD13. Sodium phenyl butyrate is a Another study has identified patients with severe histone deacetylase inhibitor (HDACI) and is found to clinical presentation of arginase deficiency (ARGD)22. reduce levels of ammonia in patients with UCD. The This study is interesting, since normally ARGD has drug has additional effects on DNA methylation, mild presentation. A novel homozygous mutation histone deacetylation and protein isoprenylation. has been identified in a Chinese patient with It creates alternative pathways for nitrogen excretion. hyperargininemia23. The primary metabolite, phenylacetate conjugates with glutamine in the liver and to form Citrullinemia Many studies have been done on the SLC25A13 phenylacetyl glutamine and is excreted in the urine14. gene, some of which are given below. Takahashi et al24 However, the drug has found to decrease the levels of detected one novel and one already reported mutation branched chain amino acids (BCAA) and it has been in Japanese patients with citrullinemia, while Lin suggested that BCAA supplementation should be et al25 identified a compound heterozygote mutation given to patients with UCD treated with sodium citrullinemia patient from China. Tabata et al26 phenyl butyrate14. reported 13 novel mutations and 19 established Sodium benzoate is another important treatment mutations in SLC25A13 gene in citrullinemia patients option. It is found that sodium benzoate can eliminate from Japan, Israel, UK and Czech Republic. They nitrogen in patients with UCD15. Prenatal sodium reported R360X mutation in both Japanese and benzoate is also postulated to have beneficial effect to Caucasian population. the fetus15. Treatment with benzoate and phenylacetate ASS1 gene mutations have been found in both is found to improve survival in patients with UCD16. paternal and maternal sides of a patient in a Liver transplantation is another mode of therapy17,18. Citrullinemia Type 1 patient27. In another study in a It has been found to reduce hyperammonemia, dietary large cohort of 35 patients with citrullinemia, 16 novel restrictions and improves neurocognitive development. mutations have been identified28; they reported from However, long-term follow-up is needed to evaluate, all their previous studies, altogether 50 different whether the liver transplantation at an early age mutations in 85 families with citrullinemia28. It is (< 1 yr) will improve the neurodevelopmental outcomes18. found that certain mutations (G390R, R108L) of the Hepatocyte transplantation is considered as an ASS gene are associated with classical citrullinemia, alternative to orthotopic liver transplantation19. whereas some other mutations (W179R, G362V) are 29 Molecular diagnosis of UCD patients associated with milder phenotype .

International scenario CPS1 deficiency A study conducted Mo et al20 suggests that patients Seventeen mutations in patients with CPSI with certain mutations exhibit more severe and early deficiency have been identified in an Italian study30. phenotype. They report that OTCD patients with Another study in 205 patients with CPS1 deficiency I172M mutation present symptoms earlier than over 24 yrs has identified 192 unique CPS1 gene those with T261I or R277W mutations. Mutation changes31; about ~10% of these mutations are found analysis hence helps prenatal diagnosis and genetic to recur in unrelated families and these affect the CpG counseling. This section summarizes the most dinucleotides. Phenotypic correlation has been found important studies in this field. Most of the studies between 9 mutations and one polymorphism in CPS1 have used DNA sequencing to detect mutations. deficient patients32. 360 INDIAN J. BIOCHEM. BIOPHYS., VOL. 50, OCTOBER 2013

Table 2—Location of UCD and common mutations identified Gene name Chromosomal location Number of exons Common mutations (*) CPS1 2q 35 38 THR544MET, GLN44TER, HIS337ARG, THR1405ASN, GLY982ASP, ARG787TER

ASL 7CED q11.2 17 ARG95CYS, GLN286ARG, ARG385CYS, VAL178MET, ARG379CYS OTC Xp21.1 10 ARG109GLN, ARG109TER, LEU111PRO, GLN216GLU, GLU154TER, LEU45PRO, ARG26GLN, LYS46ARG, ARG245TRP, ARG277TRP, PRO225LEU, GLU87LYS, GLY50TER, GLY162ARG, GLY47GLU, ARG62THR, LEU272PHE, TYR313ASP, ARG129HIS, LEU148PHE, MET206ARG, ARG40CYS, ARG40HIS ASS1 9q34 16 GLY14SER, ARG157HIS, SER180ASN, GLY324SER, ARG363TRP, GLY390ARG, ARG304TRP, SER18LEU, ARG86CYS, ARG279TER, ARG108LEU, TRP179ARG, GLY362VAL, LYS310GLN ARG1 6q23 8 ARG291TER, THR290SER, TRP122TER, GLY235ARG, ILE11THR, GLY138VAL, ARG21TER * - Reference – OMIM database (www.omim.org)

OTC deficiency all mutations are detected, and the rest occur within Twenty-five distinct mutations have been described introns or regulatory domains. in 29 families with OTC with fourteen novel ones McCullough et al40 have reported mutations in 33 found in areas essential for enzyme function . 157 families with OTCD. They found neonatal onset A multiplex ligation-dependant probe amplification group having homogeneous clinical and biochemical (MLPA) method has been reported to detect phenotype, while late-onset group having extremely 3 mutations in OTCD patients, which are undetected wide phenotype. 60% of mutations are associated by other conventional methods. This technique detects exclusively with acute neonatal hyperammonemia and deletions spanning a whole exon, large rearrangements 34 remaining mutations causing non-uniform phenotypes, or mutations at non-coding regions . ranging from severe disease to asymptomatic. 31% Three mutations (R40H, R277W and Y55D) of mutations are found to occur in CpG dinucleotides. are identified in male patients among 10 families of G to A and C to T transitions are the most common OTCD patients. It is also reported that paternal substitutions. In addition, it is seen that 40% of female transmission contributes substantially to mutant allele germline mutations are in CpG dinucleotides, while pool and the mutant alleles associated with late-onset 35 the number is much smaller in male germline mutations. phenotypes are eliminated more slowly . It is reported that the mutation Thr125Met is Indian status associated with neonatal hyperammonemia36. Another In the only study of its kind, mutation analysis study has identified 9 patients with R40H mutation from 4 patients with UCD has identified 3 patients and one patient with Y55D mutation in OTC gene and with ASS1 mutation and one patient with OTC gene has reported increase in glutamine, , lysine, mutation41. Based on DNA sequencing, the following and and decreases in serine, mutations have been detected: p.Arg265Cys in ornithine and arginine in these 10 patients37. homozygous state, p.Arg157His in homozygous state, One of the reports has found that most of p.Gly390Arg in homozygous state (all three in ASS1 the mutations in OTC gene are point mutations gene) and a hemizygous mutation, fs352X in OTC and small deletions/insertions and have a “private” gene (c.988_c.989 delAG)41. The locations of genes character (i.e., without recurrence in other families)38. responsible for UCD and the common mutations seen Tuchman et al 39 have reported a total of 244 in these genes are summarized in Table 2. mutations in OTC gene, including 24 novel mutations and 13 polymorphisms), of which 42% are associated Conclusion with acute neonatal hyperammonemia, 21% with Urea cycle disorders (UCD) are an important group late-onset disease and approximately 37% are found of inborn error of metabolism. Early diagnosis of in heterozygous female patients. They have also UCD is of paramount importance in clinical practice. reported that with conventional methods, only 80% of With early diagnosis, morbidity and mortality due to VAIDYANATHAN: MOLECULAR DIAGNOSIS OF UREA CYCLE DISORDERS 361

UCD are reduced. Molecular diagnosis not only helps NAGS (N-acetylglutamate synthase) deficiency in adults. in reaching an early diagnosis, but also helps in Can J Neurol Sci 40, 3-9 11 Ozanne B, Nelson J, Cousineau J, Lambert M, Phan V, prenatal diagnosis and genetic counseling. If we Mitchell G, Alvarez F, Ducruet T & Jouvet P (2012) employ it in routine clinical practice, the cost can be Threshold for toxicity from hyperammonemia in critically ill brought down. We might also be able to develop children. J Hepatol 56, 123-128 multiplex PCR kits which can be used for early 12 Adam S, Champion H, Daly A, Dawson S, Dixon M, Dunlop C, Eardley J, Evans S, Ferguson C, Jankowski C, diagnosis, substantially reducing the cost. This review Lowry S, MacDonald A, Maritz C, Micciche A, Robertson L, article has highlighted some of the important Stafford J, Terry A, Thom R, van Wyk K, Webster D, molecular diagnostic studies in UCD. Even though in White F J & Wildgoose J; British Inherited Metabolic many Western countries, molecular diagnosis is Diseases Group (BIMDG) Dietitian’s Group (2012) Dietary employed commonly in the diagnosis of UCD, it is management of urea cycle disorders: UK practice. J Hum Nutr Diet 25, 398-404 not commonly practiced in India. More research is 13 Smith W, Diaz G A, Lichter-Konecki U, Berry S A, Harding also essential to find the incidence patterns and C O, McCandless S E, Lemons C, Mauney J, Dickinson K, severity of the disease in India. Coakley D F, Moors T, Mokhtarani M, Scharschmidt B F & Lee B (2013) Ammonia control in children ages 2 months through 5 years with urea cycle disorders: Comparison of References and glycerol phenylbutyrate. 1 Lanpher B C, Gropman A, Chapman K A, Lichter-Konecki U, J Pediatr [Epub ahead of print] Urea Cycle Disorders Consortium & Summar ML (2011) 14 Scaglia F (2010) New insights in nutritional management Urea cycle disorders overview. In: Pagon R A, Bird T and amino acid supplementation in urea cycle disorders. D, Dolan C R, Stephens K, Adam M P, eds. GeneReviews™ Mol Genet Metab 100 Suppl 1, S72-76 [Internet]. Seattle (WA): University of Washington, Seattle; 15 Das A M, Illsinger S, Hartmann H, Oehler K, Bohnhorst B, 1993-2003, Apr 29 [updated 2011 Sep 01] Kühn-Velten W N, Lücke T (2009) Prenatal benzoate 2 Kido J, Nakamura K, Mitsubuchi H, Ohura T, Takayanagi M, treatment in urea cycle defects.. Arch Dis Child Fetal Matsuo M, Yoshino M, Shigematsu Y,Yorifuji T, Kasahara Neonatal 94, F216-217 M, Horikawa R & Endo F (2012) Long-term outcome 16 Enns G M, Berry S A, Berry G T, Rhead W J, Brusilow and intervention of urea cycle disorders in Japan. S W, Hamosh A (2007) Survival after treatment with J Inherit Metab Dis 35, 777-785 phenylacetate and benzoate for urea-cycle disorders. N Eng 3 Tuchman M, Lee B, Lichter-Konecki U, Summar M L, J Med 356:2282-2292 Yudkoff M, Cederbaum S D, Kerr D S, Diaz G A, Seashore 17 Kim I K, Niemi A K, Krueger C, Bonham C A, Concepcion W, M R, Lee H S, McCarter R J, Krischer J P & Batshaw M L Cowan T M, Enns G M & Esquivel CO (2013) Liver (2008) Cross-sectional multicenter study of patients with transplantation for urea cycle disorders in pediatric patients: urea cycle disorders in the United States. Urea Cycle a single-center experience. Pediatr Transplant 17, 158-167 Disorders Consortium of the Rare Diseases Clinical Research 18 Fagiuoli S, Daina E, D'Antiga L, Colledan M, Remuzzi G Network. Mol Genet Metab 94, 397-402 (2013) Monogenic diseases that can be cured by liver 4 Häberle J, Boddaert N, Burlina A, Chakrapani A, Dixon M, transplantation. J Hepatol [Epub ahead of print]. Huemer M, Karall D, Martinelli D, Crespo P S, Santer R, 19 Seeliger C, Culmes M, Schyschka L, Yan X, Damm G, Servais A,Valayannopoulos V, Lindner M, Rubio V & Wang Z, Kleeff J, Thasler W E, Hengstler J, Stöckle U, Dionisi-Vici C (2012) Suggested guidelines for the diagnosis Ehnert S & Nüssler A K (2013) Decrease of global and management of urea cycle disorders. Orphanet J Rare methylation improves significantly hepatic differentiation Dis 7, 32 of Ad-MSCs: Possible future application for urea 5 D M Vasudevan, Sreekumari S & K Vaidyanathan (2013) detoxification. Cell Transplant 22, 119-131 Textbook of Biochemistry (For Medical Students) 7th edn. 20 Mo W Q, Liu L, Chen Y Y, Cheng J, Li X Z, Zhou Z H, Publisher Jaypee Brothers, New Delhi, India Mao X J & Zhang W (2011) Clinical and gene mutation 6 Gropman A L, Summar M & Leonard J V (2007) analyses of three patients with ornithine carbamoyltransferase Neurological implications of urea cycle disorders. J Inherit deficiency. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 28, Metab Dis 30, 865-879 328-331 7 Enns G M (2008) Neurologic damage and neurocognitive 21 Carvalho D R, Brand G D, Brum J M, Takata R I, Speck- dysfunction in urea cycle disorders. Semin Pedaitr Neurol Martins C E & Pratesi R (2012) Analysis of novel ARG1 15, 132-139 mutations causing hyperargininemia and correlation with 8 Summar M L, Dobbelaere D, Brusilow S & Lee B (2008) arginase I activity in erythrocytes. Gene 509, 124-130 Diagnosis, symptoms, frequency and mortality of 260 22 Jain-Ghai S, Nagamani S C, Blaser S, Siriwardena K, patients withurea cycle disorders from a 21-year, multicentre Feigenbaum A (2011) Arginase I deficiency: severe infantile study of acute hyperammonaemic episodes. Acta Paediatr presentation with hyperammonemia: more common than 97, 1420-1425 reported? Mol Genet Metab 104,107-111 9 Braissant O, McLin V A & Cudalbu C (2012) Ammonia 23 Tsang J P, Poon W L, Luk H M, Fung C W, Ching C K, toxicity to the brain. J Inherit Metab Dis [Epub ahead of print] Mak C M, Lam C W, Siu T S, Tam S & Wong V C (2012) 10 Cartagena A, Prasad A N, Rupar C A, Strong M, Tuchman M, Arginase deficiency with new phenotype and a novel mutation: Ah Mew N & Prasad C (2013) Recurrent encephalopathy: contemporary summary. Pediatr Neurol 47, 263-269 362 INDIAN J. BIOCHEM. BIOPHYS., VOL. 50, OCTOBER 2013

24 Takahashi Y, Koyama S, Tanaka H, Arawaka S, Wada M, 32 Pekkala S, Martínez A I, Barcelona B, Yefimenko I, Kawanami T, Haga H, Watanabe H, Toyota K, Numakura C, Finckh U, Rubio V, Cervera J (2010) Understanding Hayasaka K & Kato T (2012) An elderly Japanese patient carbamoyl-phosphate synthetase I (CPS1) deficiency by with adult-onset type II citrullinemia with a novel D493G using expression studies and structure-based analysis. mutation in the SLC25A13 gene. Intern Med 51, 2131-2134 Hum Mutat 31, 801-808 25 Lin W X, Zhang Z H, Deng M, Cai X R & Song Y Z (2012) 33 Storkanova G, Vlaskova H, Chuzhanova N, Zeman J, Multiple ovarian antral follicles in a preterm infant with Stranecky V, Majer F, Peskova K, Luksan O, Jirsa M, neonatal intrahepatic cholestasis caused by citrin deficiency: Hrebicek M & Dvorakova L (2012) Ornithine a clinical, genetic and transcriptional analysis. Gene 505, carbamoyltransferase deficiency: molecular characterization 269-275 of 29 families. Clin Genet [Epub ahead of print] 26 Tabata A, Sheng J S, Ushikai M, Song Y Z, Gao H Z, 34 Quental R, Azevedo L, Rubio V, Diogo L & Amorim A Lu Y B, Okumura F, Iijima M, Mutoh K, Kishida S,Saheki T (2009) Molecular mechanisms underlying large genomic & Kobayashi K (2008) Identification of 13 novel mutations deletions in ornithine transcarbamylase (OTC) gene. Clin including a retrotransposal insertion in SLC25A13 gene and Genet 75, 457-464 frequency of 30 mutations found in patients with citrin 35 Numata S, Harada E, Maeno Y, Ueki I, Watanabe Y, Fujii C, deficiency. J Hum genet 53, 534-545 Yanagawa T, Takenaka S, Inoue T, Inoue S, Goushi T, 27 Faghfoury H, Baruteau J, de Baulny H O, Häberle J & Yasutake T, Mizuta T & Yoshino M (2008) Paternal Schulze A (2011) Transient fulminant liver failure as an transmission and slow elimination of mutant alleles initial presentation in . Mol Genet Metab associated with late-onset ornithine transcarbamylase 102, 413-417 deficiency in male patients. J Hum Genet 53, 10-17 28 Gao H Z, Kobayashi K, Tabata A, Tsuge H, Iijima M, 36 Suriano G, Azevedo L, Novais M, Boscolo B, Seruca R, Yasuda T, Kalkanoglu H S, Dursun A, Tokatli A,Coskun T, Amorim A & Ghibaudi E M (2007) In vitro demonstration Trefz F K, Skladal D, Mandel H, Seidel J, Kodama S, of intra-locus compensation using the ornithine Shirane S, Ichida T, Makino S,Yoshino M, Kang J H, transcarbamylase protein as model. Hum Mol Genet Mizuguchi M, Barshop B A, Fuchinoue S, Seneca S, 16, 2209-2214 Zeesman S, Knerr I,Rodés M, Wasant P, Yoshida I, De 37 Harada E, Nishiyori A, Tokunaga Y, Watanabe Y, Kuriya N, Meirleir L, Abdul Jalil M, Begum L, Horiuchi M, Katunuma Kumashiro R, Kuno T, Kuromaru R, Hirose S, Ichikawa K & N, Nakagawa S & Saheki T (2003) Identification of 16 novel Yoshino M (2006) Late-onset ornithine transcarbamylase mutations in the argininosuccinate synthetase gene and deficiency in male patients: prognostic factors and genotype-phenotype correlation in 38 classical citrullinemia characteristics of plasma amino acid profile. Pediatr Int 48, patients. Hum Mutat 22, 24-34 105-111 29 Häberle J, Pauli S, Linnebank M, Kleijer W J, Bakker H D, 38 Climent C & Rubio V (2002) Identification of seven novel Wanders R J, Harms E & Koch H G (2002) Structure of the human argininosuccinate synthetase gene and an improved missense mutations, two splice-site mutations, two system for molecular diagnostics in patients with classical microdeletions and a polymorphic amino acid substitution in and mild citrullinemia. Hum Genet 110, 327-333 the gene for ornithine transcarbamylase (OTC) in patients 30 Funghini S, Thusberg J, Spada M, Gasperini S, Parini R, with OTC deficiency. Hum Mutat 19, 185-186 Ventura L, Meli C, De Cosmo L, Sibilio M,Mooney S D, 39 Tuchman M, Jaleel N, Morizono H, Sheehy L & Lynch M G Guerrini R, Donati M A & Morrone A (2012) Carbamoyl (2002) Mutations and polymorphisms in the human ornithine phosphate synthetase 1 deficiency in Italy: clinical and genetic transcarbamylase gene. Hum Mutat 19, 93-107 findings in a heterogeneous cohort. Gene 493, 228-234. 40 McCullough B A, Yudkoff M, Batshaw M L, Wilson J M, 31 Häberle J, Shchelochkov O A, Wang J, Katsonis P, Hall L, Raper S E & Tuchman M (2000) Genotype spectrum of Reiss S, Eeds A, Willis A, Yadav M & Summar S; Urea ornithine transcarbamylase deficiency: correlation with the Cycle Disorders Consortium, Lichtarge O, Rubio V, clinical and biochemical phenotype. Am J Med Genet 93, Wong L J, Summar M (2011) Molecular defects in human 313-319 carbamoyl phosphate synthetase I: mutational spectrum, 41 Gupta N, Kabra M & Häberle J (2012) Mutation analysis of diagnostic and protein structure considerations. Hum Mutat Indian patients with urea cycle defects. Indian Pediatr 49, 32, 579-589 585-586